In our study, we does not observe a statistically significant increase of severe rash with dual anti-HER2 treatment in breast cancer patients, while sub-group analysis shows that lapatinib significantly increases the risk of severe rash which is consisted with previous research [36]. The gene discussed is ERBB2; the disease is breast cancer.